Erythema migrans

References

• Malane MS, Grant-Kels JM, Feder HM Jr, et al. Diagnosis of Lyme disease based on dermatologie manifestations. Ann Intern Med 1991:114(6):490–8
   PubMed Web of Science ®Google Scholar
• Treatment of Lyme disease. Med Lett Drugs Ther 1992;34(881):95–7
   PubMedGoogle Scholar
• Rahn DW, Malawista SE. Clinical judgment in Lyme disease. Hosp Pract Off 1990; 25(3A):39–53, 56
   PubMed Web of Science ®Google Scholar
• NIH state-of-the-art conference: diagnosis and treatment of Lyme disease. Clin Courier 1991;9(5)
   Google Scholar
• Berger BW. Dermatologic manifestations of Lyme disease. Rev Infect Dis 1989; 11 (Suppl 6): S1475–81
   PubMedGoogle Scholar
• Steere AC. Lyme disease. N Engl J Med 1989:321(9):586–96
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control, Lyme disease: Connecticut. MMWR 1988; 37(l):1–3
   PubMedGoogle Scholar
• Stanek G, Flamm H, Groh Y et al. Epidemiology of bor relia infections in Austria. Zentralbl Bakteriol Mikrobiol Hyg (A) 1987;263(3): 442–9
   PubMedGoogle Scholar
• Duffy J, Schoen KT, Sigal LH. 1991 update on Lyme disease. Patient Care 1991,25(11): 24–46
   Google Scholar
• Bakken LL, Case KL, Callister SM, et al. Performance of 45 laboratories participating in a proficiency testing program for Lyme disease serology. JAMA 1992;268(7):891–5
   PubMed Web of Science ®Google Scholar
• Asbrink E, Olsson I. Clinical manifestations of erythema chronicum migrans Afzelius in 161 patients: a comparison with Lyme disease. Acta Derm Venereol (Stockh) 1985:65(1): 43–52
   PubMed Web of Science ®Google Scholar
• Steere AC, Bartenhagen NH, Craft JE, et al. The early clinical manifestations of Lyme disease. Ann Intern Med 1983;99(l):76–82
   PubMed Web of Science ®Google Scholar
• Shih CM, Pollack RJ, Telford SR 3d, et al. Delayed dissemination of Lyme disease spirochetes from the site of deposition in the skin of mice. J Infect Dis 1992;166(4):827–31
   PubMed Web of Science ®Google Scholar
• Garda-Monco JC, Villar BF, Akan JC, et al. Borrelia burgdorferi in the central nervous system: experimental and clinical evidence for early invasion. J Infect Dis 1990;161(6):1187–93
   PubMed Web of Science ®Google Scholar
• Luft BJ, Steinman CR, Neimark C, et al. Invasion of the central nervous system by Borrelia burgdorferi in acute disseminated infection. JAMA 1992;267(10):1364–7 [erratum, JAMA 1992;268(7):872]
   PubMed Web of Science ®Google Scholar
• Berger BW, Johnson RC, Kodner C, et al. Cultivation of Borrelia burgdorferi from erythema migrans lesions and perilesional skin. J Clin Microbiol 1992;30(2):359–61
   PubMed Web of Science ®Google Scholar
• Mitchell PD, Reed KD, Vandermause MF, et al. Isolation of Borrelia burgdorferi from skin biopsy specimens of patients with erythema migrans. Am J Clin Pathol 1993;99(l):104–7
   PubMed Web of Science ®Google Scholar
• DeKoning J, Bosma RB, Hoogkamp-Korstanje JA. Demonstration of spirochaetes in patients with Lyme disease with a modified silver stain. J Med Microbiol 1987;23(3):261–7
   PubMed Web of Science ®Google Scholar
• Aberer E, Duray PH. Morphology of Borrelia burgdorferi: structural patterns of cultured borreliae in relation to staining methods. J Clin Microbiol 1991;29(4):764–72
   PubMed Web of Science ®Google Scholar
• Wormser GP, Forseter G, Cooper D, et al. Use of a novel technique of cutaneous lavage for diagnosis of Lyme disease associated with erythema migrans. JAMA 1992;268(10):1311–3
   PubMed Web of Science ®Google Scholar
• Rahn DW. Antibiotic treatment of Lyme disease: current recommendations by stage and extent of infection. Postgrad Med 1992;91(7): 57–64
   PubMed Web of Science ®Google Scholar
• Nadelman RB, Luger SW, Frank E, et al. Comparison of cefuroxime axetil and doxycycline in the treatment of early Lyme disease. Ann Intern Med 1992;117(4):273–80
   PubMed Web of Science ®Google Scholar
• Massarotti EM, Luger SW Rahn DW, et al. Treatment of early Lyme disease. Am J Med 1992; 92(4): 396–403
   PubMed Web of Science ®Google Scholar
• Dever LL, Jorgensen JH, Barbour AG. In vitro antimicrobial susceptibility testing of Borrelia burgdorferi: a microdilution MIC method and time-kill studies. J Clin Microbiol 1992; 30(10):2692–7
   PubMed Web of Science ®Google Scholar
• Nelson JA, Segreti J, Levin J, et al. In-vitro susceptibility of Borrelia burgdorferi. Abstracts, Fifth International Conference on Lyme Borreliosis. Arlington, Va: 1992 May 30-June 2, abstr69
   Google Scholar
• Luft BJ, Luger SW Rahn DW et al. Azithromycin and amoxicillin for the treatment of erythema migrans: preliminary analysis of a double-blind trial. Ibid, abstr 56
   Google Scholar
• Agger WA, Callister SM, Jobe DA. In vitro susceptibilities of Borrelia burgdorferi to five oral cephalosporins and ceftriaxone. Antimicrob Agents Chemother 1992;36(8):1788–90
   PubMed Web of Science ®Google Scholar
• Dotevall L, Hagberg L. Penetration of doxycycline into cerebrospinal fluid in patients treated for suspected Lyme neuroborreliosis. Antimicrob Agents Chemother 1989:33(7): 1078–80
   PubMed Web of Science ®Google Scholar
• Berger BW, Johnson RC, Kodner C, et al. Failure of Borrelia burgdorferi to survive in the skin of patients with antibiotic-treated Lyme disease. J Am Acad Dermatol 1992;27(l):34–7
   PubMed Web of Science ®Google Scholar
• Georgilis K, Peacocke M, Klempner MS. Fibroblasts protect the Lyme disease spirochete, Borrelia burgdorferi, from ceftriaxone in vitro. J Infect DB 1992;166(2):440–4
   PubMed Web of Science ®Google Scholar
• Dattwyler RJ Halperin JJ. Failure of tetracycline therapy in early Lyme disease. Arthritis Rheum 1987:30(4):448–50
   PubMed Web of Science ®Google Scholar
• Liegner KB, Shapiro JR, Ramsay D, et al. Recurrent erythema migrans despite extended antibiotic treatment with minocycline in a patient with persisting Borretia burgdorferi infection. J Am Acad Dermatol 1993:28(2 Pt 2): 312–4
   PubMed Web of Science ®Google Scholar